Daiichi Sankyo has signed a research and commercial agreement with BioWa, Inc. and Lonza to use their POTELLIGENT® CHOK1SV cell line for the development and production of recombinant antibodies.
POTELLIGENT® CHOK1SV is a new host cell line for manufacturing recombinant antibodies that combines the power of BioWa’s engineered glycosylation POTELLIGENT® Technology with the advantages of Lonza’s proprietary GS Gene Expression System™, which includes the industry-leading cell line CHOK1SV.
“We are pleased POTELLIGENT® CHOK1SV has been chosen by Daiichi Sankyo to be a strategic part of its biological drug development program,” said John Birch, CSO of Lonza Biopharmaceuticals. “We look forward to supporting Daiichi Sankyo’s R&D efforts and to a long-lasting, successful collaboration.”
“This is the first announced licensing of POTELLIGENT® CHOK1SV. Selection of the new cell line by a leading research and development organization such as Daiichi Sankyo is an important indication of its potential utility for the therapeutic antibody field,” said Dr. Masamichi Koike, President and CEO of BioWa.
Advantages of the POTELLIGENT® CHOK1SV Cell Line
- The POTELLIGENT® CHOK1SV cell line retains the desirable features of a high-productivity cell line (robust, high-yielding, scalable)
- Proven bioprocess platform for CHOK1SV is repeatable in the new cell line
- Antibodies produced by the new cell line:
- Exhibit enhanced antibody dependent cellular cytotoxicity (ADCC)
- Can exert potent cytotoxic effects when their target antigen is low-density
- Work in whole blood
- Retain all the other desirable features of antibodies
The POTELLIGENT® CHOK1SV cell line is available as one of the options in Lonza cell line construction offerings. To learn more about the benefits of POTELLIGENT® CHOK1SV, please contact one of our experts at +44 (0) 1753 777 000 or GSLonza@lonza.com
About POTELLIGENT® Technology
POTELLIGENT® Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT® Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT® Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo. A number of POTELLIGENT® antibodies are being investigated in human clinical trials.
About the GS Gene Expression System™
The GS Gene Expression System™, which is owned and licensed by Lonza, is used for the production of therapeutic recombinant proteins and monoclonal antibodies. Nearly 100 biotechnology and pharmaceutical companies and over 75 academic laboratories worldwide are successfully using the GS Gene Expression System™ which has established itself as the industry standard. This system is characterized by its speed and ease of use. In addition, the higher yielding cell lines provide cost-efficient production of therapeutic proteins.
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets. Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2009, Lonza had sales of CHF 2.690 billion. Further information can be found at www.lonza.com.
About BioWa, Inc.
BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan's leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of the AccretaMab® platform. The AccretaMab® platform consists of POTELLIGENT® and COMPLEGENT® Technologies, creating a superior antibody molecule with enhanced ADCC and CDC activities. BioWa is offering POTELLIGENT® and COMPLEGENT® Technologies to partners under a license to maximize the value of these technologies. Together with Kyowa Hakko Kirin, BioWa is committed to promote ADCC/CDC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. For more information about BioWa, visit its web site at www.biowa.com. POTELLIGENT®, COMPLEGENT®, and AccretaMab® are the trademarks of Kyowa Hakko Kirin Co., Ltd. All rights are reserved.
About Daiichi Sankyo
The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com
For further information:
Lonza Group Ltd
Head Corporate Communications
Tel +41 61 316 8624
Fax +41 61 316 9624
Lonza Group Ltd
Tel +41 61 316 8798
Fax +41 61 316 9798
Lonza Group Ltd
Tel +41 61 316 8540
Fax +41 61 316 9540
Masamichi Koike, Ph.D.
President and CEO
Tel +1 609 580 7500